Payment overview · 2025
General Payments
$393.22
21 reported records · 9 companies
Healthcare provider profile · identity verified
Suhas R Patel, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · OCEAN, NJ · NPI 1104844778
Verified facts
What the public records show
CMS Open Payments records show Suhas R Patel, M.D received $393.22 in general payments during 2025 across 21 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 453 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $99.12 | 25.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.17 | 15.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.93 | 13.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.98 | 13.0% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $41.16 | 10.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.12 | 9.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.71 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.17 | 4.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.86 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $393.22 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $112.98 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.17 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $41.16 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
453 | 77 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 635 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 515 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 503 | 88 |
| Gabapentin | Gabapentin | 487 | 57 |
| Eliquis | Apixaban | 453 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 97 |
| Sertraline Hcl | Sertraline Hcl | 424 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 406 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 68 |
| Losartan Potassium | Losartan Potassium | 346 | 59 |
| Donepezil Hcl | Donepezil Hcl | 345 | 68 |
| Mirtazapine | Mirtazapine | 309 | 49 |
| Trazodone Hcl | Trazodone Hcl | 309 | 31 |
| Furosemide | Furosemide | 286 | 72 |
| Xarelto | Rivaroxaban | 259 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 58 |
| Metformin Hcl | Metformin Hcl | 237 | 37 |
| Lisinopril | Lisinopril | 224 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 213 | 42 |
| Omeprazole | Omeprazole | 211 | 37 |
| Famotidine | Famotidine | 189 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 177 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 168 | 16 |
| Celecoxib | Celecoxib | 157 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 16 |
| Warfarin Sodium | Warfarin Sodium | 150 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 23 |
| Potassium Chloride | Potassium Chloride | 121 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 14 |
| Levetiracetam | Levetiracetam | 101 | 20 |
| Montelukast Sodium | Montelukast Sodium | 99 | 24 |
| Finasteride | Finasteride | 98 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 98 | 18 |
| Carvedilol | Carvedilol | 94 | 34 |
| Simvastatin | Simvastatin | 93 | 18 |
| Alprazolam | Alprazolam | 91 | 32 |
| Spironolactone | Spironolactone | 89 | 25 |
| Memantine Hcl | Memantine Hcl | 87 | 16 |
| Lactulose | Lactulose | 86 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 30 |
| Midodrine Hcl | Midodrine Hcl | 84 | 32 |
| Sucralfate | Sucralfate | 84 | 13 |
| Valsartan | Valsartan | 72 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 37 |
| Divalproex Sodium | Divalproex Sodium | 70 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 70 | suppressed |
| Nystatin | Nystatin | 69 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 14 |
| Tramadol Hcl | Tramadol Hcl | 63 | 20 |
| Eplerenone | Eplerenone | 61 | suppressed |
| Latanoprost | Latanoprost | 61 | 17 |
| Lovastatin | Lovastatin | 61 | suppressed |
| Aripiprazole | Aripiprazole | 59 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 15 |
| Prednisone | Prednisone | 58 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 11 |
| Allopurinol | Allopurinol | 56 | 18 |
| Buspirone Hcl | Buspirone Hcl | 56 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 11 |
| Ezetimibe | Ezetimibe | 54 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 19 |
| Methocarbamol | Methocarbamol | 50 | suppressed |
| Fenofibrate | Fenofibrate | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | 12 |
| Meloxicam | Meloxicam | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | 11 |
| Bupropion Xl | Bupropion Hcl | 43 | 11 |
| Baclofen | Baclofen | 42 | suppressed |
| Hydrocortisone | Hydrocortisone | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 22 |
| Bumetanide | Bumetanide | 37 | 12 |
| Cephalexin | Cephalexin | 36 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Nystop | Nystatin | 33 | 23 |
| Cefuroxime | Cefuroxime Axetil | 32 | 26 |
| Digoxin | Digoxin | 32 | 16 |
| Humalog | Insulin Lispro | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | 11 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 21 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 16 |
| Torsemide | Torsemide | 29 | 16 |
| Azithromycin | Azithromycin | 28 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 19 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | 11 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Loperamide | Loperamide Hcl | 22 | 13 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 12 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 11 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 13 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Tivicay | Dolutegravir Sodium | 16 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $393.22 · 21 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, AMYVID, BREZTRI, Cologuard Collection Kit, KISUNLA, Leqembi, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error